AbbVie Inc. Net Debt/EBITDA

Net Debt/EBITDA of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Debt/EBITDA growth rates and interactive chart.


Highlights and Quick Summary

  • Net Debt/EBITDA for the quarter ending December 30, 2020 was 13.33 (a -6.5% decrease compared to previous quarter)
  • Year-over-year quarterly Net Debt/EBITDA increased by 114.24%
  • Annual Net Debt/EBITDA for 2020 was 4.35 (a 143.43% increase from previous year)
  • Annual Net Debt/EBITDA for 2019 was 1.79 (a -54.85% decrease from previous year)
  • Annual Net Debt/EBITDA for 2018 was 3.96 (a 58.53% increase from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Debt/EBITDA of AbbVie Inc.

Most recent Net Debt/EBITDAof ABBV including historical data for past 10 years.

Interactive Chart of Net Debt/EBITDA of AbbVie Inc.

AbbVie Inc. Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 13.33 14.26 35.28 6.22 4.35
2019 6.0 8.9 8.16 9.09 1.79
2018 -16.13 8.83 10.41 8.31 3.96
2017 12.82 9.19 9.88 11.04 2.5
2016 11.51 11.02 11.15 9.16 2.89
2015 9.8 10.83 11.19 3.98 2.78
2014 -29.74 3.88 2.62 3.42 1.57
2013 2.78 3.25 3.55 4.93 0.74
2012 3.61 -2.52 -0.04 -0.03 1.1
2011 0.11 0.0 0.0 0.0 -0.12
2010 0.0 -0.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.